text:
Our 2017 Gala Was a Spirited, Wonderful Evening!
We had a wonderful, enjoyable and uplifting Gala as we honored Allen L. Rothenberg with our Pillar of the Community Award, Jonathan Tobin with our Ben Hecht Award for Outstanding Journalism; Rabbi Yaacov Orimland with our Guardian of Israel Award, and Jim and Diane Showers with our Friends of Zion Award. See a sampling of
EBulletin for Sept. 1, 2017
Shalom ZOA Members, Friends and Supporters of Israel, We are eagerly looking forward to welcoming many of you to our annual Gala, taking place just less than two weeks from now – on September 12. Tickets for the Gala are available now. While we look forward to seeing and being with so many of our
ZOA: Hostile-to-Israel Propagandist David Myers Should Not Lead Center for Jewish History
Zionist Organization of America (ZOA) President Morton A. Klein released the following statement: After investigating David Myers' anti-Israel agenda-driven "history scholarship," other writings, affiliations and involvements with anti-Israel organizations, and his anti-Israel activities at UCLA, the ZOA is convinced that David Myers should not head the Center for Jewish History ("CJH"), and should be removed [...]
Head of Iran's Atomic Energy Commission: Iran Can Quickly Re-Activate Arak Plutonium Facility
The Zionist Organization of America (ZOA) has pointed to a recent explicit statement by the head of Iran's Atomic Energy Organization that Tehran can restore its Arak plutonium facility, supposedly deactivated as a plutonium processing facility by the 2015 Iran nuclear deal, to produce plutonium. Plutonium is an essential element in the manufacture of nuclear [...]
Greater Philadelphia ZOA Responds to Criticism for Op-Ed
Shalom ZOA Members, Friends and Supporters of Israel, Last week, the Jewish Exponent newspaper published an op-ed written by our co-presidents, Lee Bender and Kevin Ross, and our executive director, Steve Feldman, that was sharply critical of the Foreign Policy Research Institute (FPRI) and its president for an event they had recently giving a platform
When is Media Going to Treat Israelis as Indigenous?
By Lee Bender June 6, 2016 WHEN IS THE MEDIA GOING TO TREAT ISRAEL AS AN, INDIGENOUS, ABORIGINAL FIRST NATION ? WHEN JEWS ACT LIKE IT IS !! Unbeknownst to most, Jews are a People, Judaism is their religion, and the Land of Israel is their ancestral homeland—an unbroken history of 3,500 years– and


text:
India is one of Nokia's biggest markets and the Finnish telecom major has provided the lower segment buyers with a lot of useful noteworthy features, one instance being Life Tools.
Reports now claim that the mobile phone major is looking at launching a Rs. 500 mobile phone for the rural markets. Armed with Life Tools and just the very basic features Nokia could in all probability be able to pull off its $10 or Rs. 500 mobile phone.
Do you think this will come to fruition and if it does do you think it will be a successful initiative? Let us know in our comments section below.
Published Date: Feb 10, 2010 01:10 pm | Updated Date: Feb 10, 2010 01:10 pm

subset: commoncrawl


text:
By Kia Wassenaar
April 24, 2015
Wednesday, April 15: the downtown mall came alive with colorful concert goers. People of all ages streamed down the mall, headed for the Snoop Dogg concert at the N'telos Wireless pavillion. The night was warm and summery, a perfect way to kick off the Charlottesville concert season.
The doors opened at six and by seven thirty the Pavilion was packed. Wandering through the crowd, one could see nearly every age, ethnicity, and style represented. Teenagers and college students intermixed with a much older crowd. The opening DJ, Thomas Deane, played upbeat hits from the 80's and 90's and people were dancing long before Snoop came on stage. The environment was as carefree and mellow as a concert can be.
A little before nine Snoop Dogg hit the stage, opening with a crowd pleaser I Wanna Rock. He made no introduction but instead danced around the stage, characteristically zonked out and cocky. He had the crowd entirely enraptured and he knew it.
Snoop's set list was what made the concert great. He played the hits, the songs every person could and did sing along to. Songs like Gin and Juice or Dr. Dre's The Next Episode had everybody grooving out. But Snoop Dogg also covered crowd favorites like Wiggle by Jason Derulo or I Love Rock'n Roll by Joan Jett and the Blackhearts that literally had hundreds singing every word. One surprising moment was when he pulled out a joint of marijuana on stage and smoked it, a daring but fitting move for the infamous Snoop.
He kept the crowd engaged the whole time. The concert was one long crescendo that ended to a cover of Jamming by Bob Marley and the Wailers after only an hour and a half. Although the music was great, and Snoop's stage presence was very memorable, the abrupt ending of the show (he walked off without any parting words) left the whole crowd confused and honestly, a little cheated.
Overall though, I would call the concert a success. Great lighting, excellent and unusual set list, and most importantly, enthusiastic crowd. Snoop has true fans and the turnout proved it.
Snoop Dogg has been at the forefront of pop culture for years now. He's played shows around the world and has collaborated with countless major artists since he first started rapping in 1992 (including Dr. Dre, Katy Perry, and Pharrell Williams.) This year, Snoop has 23 tour stops planned across the globe (find a full list here: http://www.songkick.com/artists/292668-snoop-dogg).
Keep an eye out for his upcoming concerts!
Categories: Music Reviews


text:
Drugs Details
- Drugs Type : Multum
- Date : 21st Feb 2015 02:32 am
- Brand Name : Relafen
- Generic Name : nabumetone (Pronunciation: na BUE me tone)
RELAFEN (nabumetone) is a naphthylalkanone designated chemically as 4-(6-methoxy-2-naphthalenyl)-2-butanone. It has the following structure:
Nabumetone is a white to off-white crystalline substance with a molecular weight of 228.3. It is nonacidic and practically insoluble in water, but soluble in alcohol and most organic solvents. It has an n-octanol: phosphate buffer partition coefficient of 2400 at pH 7.4.
Tablets for Oral Administration: Each oval-shaped, film-coated tablet contains 500 mg or 750 mg of nabumetone. Inactive ingredients consist of hypromellose, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium lauryl sulfate, sodium starch glycolate, and titanium dioxide. The 750-mg tablets also contain iron oxides.
What are the possible side effects of nabumetone (Relafen)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking nabumetone and seek medical attention or call your doctor at once if you have any of these serious side effects:
- chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance;
- black, bloody, or tarry stools;
- coughing up blood or vomit that looks like coffee grounds;
- swelling or rapid weight gain;
- urinating less than usual or not at...
Read All Potential Side Effects and See Pictures of Relafen »
What are the precautions when taking nabumetone (Relafen)?
See also Warning section.
Before taking nabumetone, tell your doctor or pharmacist if you are allergic to it; or to aspirin or other NSAIDs (such as ibuprofen, naproxen, celecoxib); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: asthma (including a history of worsening breathing after taking aspirin or other NSAIDs), bleeding or clotting problems, growths in the nose (nasal polyps), heart disease (such as previous heart attack), high blood pressure, liver disease, stroke, stomach/intestinal/esophagus problems (such as bleeding, ulcers, recurring...
Read All Potential Precautions of Relafen »
Carefully consider the potential benefits and risks of RELAFEN (nabumetone) and other treatment options before deciding to use RELAFEN (nabumetone) . Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
RELAFEN (nabumetone) is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Carefully consider the potential benefits and risks of RELAFEN (nabumetone) and other treatment options before deciding to use RELAFEN (nabumetone) . Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
After observing the response to initial therapy with RELAFEN (nabumetone) , the dose and frequency should be adjusted to suit an individual patient's needs.
Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose is 1,000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1,500 mg to 2,000 mg per day. RELAFEN (nabumetone) can be given in either a single or twice-daily dose. Dosages greater than 2,000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment (see WARNINGS, Renal Effects). Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients' requirements.
Tablets: Oval-shaped, film-coated: 500 mg-white, imprinted with the product name RELAFEN (nabumetone) and 500, in bottles of 100, and in Single-Unit Packages of 100 (intended for institutional use only). 750 mg-beige, imprinted with the product name RELAFEN (nabumetone) and 750, in bottles of 100, and in Single-Unit Packages of 100 (intended for institutional use only).
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in well-closed container; dispense in light-resistant container.
500 mg 100's: NDC 0029-4851-20
500 mg SUP 100's: NDC 0029-4851-21
750 mg 100's: NDC 0029-4852-20
Research Triangle Park, NC 27709
©2005, GlaxoSmithKline. All rights reserved.
FDA rev date: 1/24/2006
Adverse reaction information was derived from blinded-controlled and open-labelled clinical trials and from worldwide marketing experience. In the description below, rates of the more common events (greater than 1%) and many of the less common events (less than 1%) represent results of US clinical studies.
Of the 1,677 patients who received RELAFEN (nabumetone) during US clinical trials, 1,524 were treated for at least 1 month, 1,327 for at least 3 months, 929 for at least a year, and 750 for at least 2 years. More than 300 patients have been treated for 5 years or longer.
The most frequently reported adverse reactions were related to the gastrointestinal tract and included diarrhea, dyspepsia, and abdominal pain.
Incidence ≥ 1%-Probably Causally Related
Gastrointestinal: Diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation*, flatulence*, nausea*, positive stool guaiac*, dry mouth, gastritis, stomatitis, vomiting.
Central Nervous System: Dizziness*, headache*, fatigue, increased sweating, insomnia, nervousness, somnolence.
Dermatologic: Pruritus*, rash*.
Special Senses: Tinnitus*. Miscellaneous: Edema*.
*Incidence of reported reaction between 3% and 9%. Reactions occurring in 1% to 3% of the patients are unmarked.
Incidence <1%-Probably Causally Related†
Gastrointestinal: Anorexia, jaundice, duodenal ulcer, dysphagia, gastric ulcer, gastroenteritis, gastrointestinal bleeding, increased appetite, liver function abnormalities, melena, hepatic failure.
Central Nervous System: Asthenia, agitation, anxiety, confusion, depression, malaise, paresthesia, tremor, vertigo.
Dermatologic: Bullous eruptions, photosensitivity, urticaria, pseudoporphyria cutanea tarda, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome.
Cardiovascular: Vasculitis.
Metabolic: Weight gain.
Respiratory: Dyspnea, eosinophilic pneumonia, hypersensitivity pneumonitis, idiopathic interstitial pneumonitis.
Genitourinary: Albuminuria, azotemia, hyperuricemia, interstitial nephritis, nephrotic syndrome, vaginal bleeding, renal failure.
Special Senses: Abnormal vision.
Hematologic/Lymphatic: Thrombocytopenia.
Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioneurotic edema.
†Adverse reactions reported only in worldwide postmarketing experience or in the literature, not seen in clinical trials, are considered rarer and are italicized.
Incidence <1%-Causal Relationship Unknown
Gastrointestinal: Bilirubinuria, duodenitis, eructation, gallstones, gingivitis, glossitis, pancreatitis, rectal bleeding.
Central Nervous System: Nightmares.
Dermatologic: Acne, alopecia.
Cardiovascular: Angina, arrhythmia, hypertension, myocardial infarction, palpitations,syncope, thrombophlebitis.
Respiratory: Asthma, cough.
Genitourinary: Dysuria, hematuria, impotence, renal stones.
Special Senses: Taste disorder.
Body as a Whole: Fever, chills.
Hematologic/Lymphatic: Anemia, leukopenia, granulocytopenia.
Metabolic/Nutritional: Hyperglycemia, hypokalemia, weight loss.
Read the Relafen (nabumetone) Side Effects Center for a complete guide to possible side effects
ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
Aspirin: When RELAFEN (nabumetone) is administered with aspirin, its protein binding is reduced, although the clearance of free RELAFEN (nabumetone) is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of nabumetone and aspirin is not generally recommended because of the potential of increased adverse effects.
Diuretics: Clinical studies, as well as post marketing observations, have shown that RELAFEN (nabumetone) can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see PRECAUTIONS, Renal Effects), as well as to assure diuretic efficacy.
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.
Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
In vitro studies have shown that, because of its affinity for protein, 6MNA may displace other protein-bound drugs from their binding site. Caution should be exercised when administering RELAFEN (nabumetone) with warfarin since interactions have been seen with other NSAIDs.
Concomitant administration of an aluminum-containing antacid had no significant effect on the bioavailability of 6MNA. When administered with food or milk, there is more rapid absorption; however, the total amount of 6MNA in the plasma is unchanged (see CLINICAL PHARMACOLOGY, Pharmacokinetics).
Read the Relafen Drug Interactions Center for a complete guide to possible interactions
Cardiovascular Thrombotic Events: Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.
There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see WARNINGS, Gastrointestinal Effects-Risk of Ulceration, Bleeding, and Perforation).
Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS).
Hypertension: NSAIDs, including RELAFEN (nabumetone) , can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including RELAFEN (nabumetone) , should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
Congestive Heart Failure and Edema: Fluid retention and edema have been observed in some patients taking NSAIDs. RELAFEN (nabumetone) should be used with caution in patients with fluid retention or heart failure.
Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation: NSAIDs, including RELAFEN (nabumetone) , can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only 1 in 5 patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for 1 year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.
In controlled clinical trials involving 1,677 patients treated with RELAFEN (nabumetone) (1,140 followed for 1 year and 927 for 2 years), the cumulative incidence of peptic ulcers was 0.3% (95% CI; 0%, 0.6%) at 3 to 6 months, 0.5% (95% CI; 0.1%, 0.9%) at 1 year and 0.8% (95% CI; 0.3%, 1.3%) at 2 years. In patients with active peptic ulcer, physicians must weigh the benefits of therapy with RELAFEN (nabumetone) against possible hazards, institute an appropriate ulcer treatment regimen and monitor the patients' progress carefully.
NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.
Renal Effects: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID results in a dose-dependent decrease in prostaglandin synthesis and, secondarily, in a reduction of renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. Discontinuation of NSAID therapy is typically followed by recovery to the pretreatment state.
Advanced Renal Disease: No information is available from controlled clinical studies regarding the use of RELAFEN (nabumetone) in patients with advanced renal disease. Therefore, treatment with RELAFEN (nabumetone) is not recommended in these patients with advanced renal disease. If RELAFEN (nabumetone) therapy must be initiated, close monitoring of the patient's renal function is advisable.
Because nabumetone undergoes extensive hepatic metabolism, no adjustment of the dosage of RELAFEN (nabumetone) is generally necessary in patients with mild renal insufficiency; however, as with all NSAIDs, patients with impaired renal function should be monitored more closely than patients with normal renal function (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Renal Insufficiency). In subjects with moderate renal impairment (creatinine clearance 30 to 49 mL/min) there is a 50% increase in unbound plasma 6MNA and dose adjustment may be warranted. The oxidized and conjugated metabolites of 6MNA are eliminated primarily by the kidneys.
Anaphylactoid Reactions: As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to RELAFEN (nabumetone) . RELAFEN (nabumetone) should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS, General, Preexisting Asthma). Emergency help should be sought in cases where an anaphylactoid reaction occurs.
Skin Reactions: NSAIDs, including RELAFEN (nabumetone) , can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
Pregnancy: In late pregnancy, as with other NSAIDs, RELAFEN (nabumetone) should be avoided because it may cause premature closure of the ductus arteriosus.
General: RELAFEN (nabumetone) cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.
The pharmacological activity of RELAFEN (nabumetone) in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
Hepatic Effects: Borderline elevations of 1 or more liver function tests may occur in up to 15% of patients taking NSAIDs including RELAFEN (nabumetone) . These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with RELAFEN (nabumetone) . If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), RELAFEN (nabumetone) should be discontinued.
Hematological Effects: Anemia is sometimes seen in patients receiving NSAIDS, including RELAFEN (nabumetone) . This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including RELAFEN (nabumetone) , should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving RELAFEN (nabumetone) who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored (see CLINICAL PHARMACOLOGY, Special Studies, Other).
Preexisting Asthma: Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, RELAFEN (nabumetone) should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
Photosensitivity: Based on ultraviolet (U.V.) light photosensitivity testing, RELAFEN (nabumetone) may be associated with more reactions to sun exposure than might be expected based on skin tanning types.
Information for Patients: Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.
- RELAFEN (nabumetone) , like other NSAIDs, may cause serious CV side effects, such as MI or stroke, which may result in hospitalization and even death. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up (see WARNINGS, CARDIOVASCULAR EFFECTS).
- RELAFEN (nabumetone) , like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up (see WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation).
- RELAFEN (nabumetone) , like other NSAIDs, can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible
- Patients should promptly report signs or symptoms of unexplained weight gain or edema to their physicians.
- Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.
- Patients should be informed of the signs of an anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see WARNINGS).
- In late pregnancy, as with other NSAIDs, RELAFEN (nabumetone) should be avoided because it may cause premature closure of the ductus arteriosus.
Laboratory Tests: Because serious G.I. tract ulceration and bleeding can occur without warning symptoms, physicians should monitor for signs and symptoms of GI bleeding. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, RELAFEN (nabumetone) should be discontinued.
Carcinogenesis, Mutagenesis: In 2-year studies conducted in mice and rats, nabumetone had no statistically significant tumorigenic effect. Nabumetone did not show mutagenic potential in the Ames test and mouse micronucleus test in vivo; however, nabumetone- and 6MNA-treated lymphocytes in culture showed chromosomal aberrations at 80 mcg/mL and higher concentrations (equal to the average human exposure to RELAFEN (nabumetone) at the maximum recommended dose).
Impairment of Fertility: Nabumetone did not impair fertility of male or female rats treated orally at doses of 320 mg/kg/day (1,888 mg/m2) before mating.
Pregnancy: Teratogenic Effects: Pregnancy Category C. Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. There are no adequate, well-controlled studies in pregnant women. RELAFEN (nabumetone) should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nonteratogenic Effects: Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.
Labor and Delivery: In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of RELAFEN (nabumetone) on labor and delivery in pregnant women are unknown.
Nursing Mothers: It is not known whether this drug is excreted in human milk, however 6MNA is excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from RELAFEN (nabumetone) , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older). Of the 1,677 patients in US clinical studies who were treated with RELAFEN (nabumetone) , 411 patients (24%) were 65 years or older; 22 patients (1%) were 75 years or older. No overall differences in efficacy or safety were observed between these older patients and younger ones. Similar results were observed in a 1-year, non-US postmarketing surveillance study of 10,800 patients treated with RELAFEN (nabumetone) , of whom 4,577 patients (42%) were 65 years or older.
Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.
Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. There are no specific antidotes. Emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 g/kg in children), and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.
There have been overdoses of up to 25 grams of RELAFEN (nabumetone) reported with no long-term sequelae following standard emergency treatment (i.e., activated charcoal, gastric lavage, IV H -blockers, etc.).
RELAFEN (nabumetone) is contraindicated in patients with known hypersensitivity to nabumetone or its excipients.
RELAFEN (nabumetone) should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS, Anaphylactoid Reactions, and PRECAUTIONS, General, Preexisting Asthma).
RELAFEN (nabumetone) is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
RELAFEN (nabumetone) is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.
The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis.
It is acidic and has an n-octanol:phosphate buffer partition coefficient of 0.5 at pH 7.4.
Pharmacokinetics: After oral administration, approximately 80% of a radiolabelled dose of nabumetone is found in the urine, indicating that nabumetone is well absorbed from the gastrointestinal tract. Nabumetone itself is not detected in the plasma because, after absorption, it undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1,000-mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. Following oral administration of RELAFEN (nabumetone) , 6MNA exhibits pharmacokinetic characteristics that generally follow a one-compartment model with first order input and first order elimination.
6MNA is more than 99% bound to plasma proteins. The free fraction is dependent on total concentration of 6MNA and is proportional to dose over the range of 1,000 mg to 2,000 mg. It is 0.2% to 0.3% at concentrations typically achieved following administration of 1,000 mg of RELAFEN (nabumetone) and is approximately 0.6% to 0.8% of the total concentrations at steady state following daily administration of 2,000 mg.
Steady-state plasma concentrations of 6MNA are slightly lower than predicted from single-dose data. This may result from the higher fraction of unbound 6MNA which undergoes greater hepatic clearance.
Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA in the plasma but does not affect the extent of conversion of nabumetone into 6MNA. Peak plasma concentrations of 6MNA are increased by approximately one third.
Coadministration with an aluminum-containing antacid had no significant effect on the bioavailability of 6MNA.
Table 1. Mean Pharmacokinetic Parameters of Nabumetone Active Metabolite (6MNA) at Steady State Following Oral Administration of 1,000-mg or 2,000-mg Doses of RELAFEN (nabumetone)
|Young Adults
Mean ± SD
1,000 mg
n = 31
|Young Adults
Mean ± SD
2,000 mg
n = 12
Mean ± SD
1,000 mg
n = 27
|Tmax (hr)
|3.0 (1.0 to 12.0)
|2.5 (1.0 to 8.0)
|4.0 (1.0 to 10.0)
|t½ (hr)
|22.5 ± 3.7
|26.2 ± 3.7
|29.8 ± 8.1
|CLss/F (mL/min)
|26.1 ± 17.3
|21.0 ± 4.0
|18.6 ± 13.4
|VDss/F (L)
|55.4 ± 26.4
|53.4 ± 11.3
|50.2 ± 25.3
The simulated curves in the graph below illustrate the range of active metabolite plasma concentrations that would be expected from 95% of patients following 1,000-mg to 2,000-mg doses to steady state. The cross-hatched area represents the expected overlap in plasma concentrations due to intersubject variation following oral administration of 1,000 mg to 2,000 mg of RELAFEN (nabumetone) .
6MNA undergoes biotransformation in the liver, producing inactive metabolites that are eliminated as both free metabolites and conjugates. None of the known metabolites of 6MNA has been detected in plasma. Preliminary in vivo and in vitro studies suggest that unlike other NSAIDs, there is no evidence of enterohepatic recirculation of the active metabolite. Approximately 75% of a radiolabelled dose was recovered in urine in 48 hours. Approximately 80% was recovered in 168 hours. A further 9% appeared in the feces. In the first 48 hours, metabolites consisted of:
|-nabumetone, unchanged
|not detectable
|-6-methoxy-2-naphthylacetic acid (6MNA), unchanged
|-6MNA, conjugated
|-6-hydroxy-2-naphthylacetic acid (6HNA), unchanged
|-6HNA, conjugated
|-4-(6-hydroxy-2-naphthyl)-butan-2-ol, Conjugated
|-O-desmethyl-nabumetone, conjugated
|-unidentified minor metabolites
|Total % Dose:
Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
Elderly Patients: Steady-state plasma concentrations in elderly patients were generally higher than in young healthy subjects (see Table 1 for summary of pharmacokinetic parameters).
Renal Insufficiency: In moderate renal insufficiency patients (creatinine clearance 30 to 49 mL/min), the terminal half-life of 6MNA was increased by approximately 50% (39.2 ± 7.8 hrs, N=12) compared to the normal subjects (26.9 ± 3.3 hrs, N=13), and there was a 50% increase in the plasma levels of unbound 6MNA.
Additionally, the renal excretion of 6MNA in the moderate renal impaired patients decreased on average by 33% compared to that in the normal patients. A similar increase in the mean terminal half-life of 6MNA was seen in a small study of patients with severe renal dysfunction (creatine clearance <30 mL/min). In patients undergoing hemodialysis, steady-state plasma concentrations of the active metabolite 6MNA were similar to those observed in healthy subjects. Due to extensive protein binding, 6MNA is not dialyzable.
Dosage adjustment of RELAFEN (nabumetone) generally is not necessary in patients with mild renal insufficiency (≥ 50 mL/min). Caution should be used in prescribing RELAFEN (nabumetone) to patients with moderate or severe renal insufficiency. The maximum starting doses of RELAFEN (nabumetone) in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful monitoring of renal function in patients with moderate or severe renal insufficiency, daily doses may be increased to a maximum of 1,500 mg and 1,000 mg, respectively (see WARNINGS, Renal Effects).
Hepatic Impairment: Data in patients with severe hepatic impairment are limited. Biotransformation of nabumetone to 6MNA and the further metabolism of 6MNA to inactive metabolites is dependent on hepatic function and could be reduced in patients with severe hepatic impairment (history of or biopsy-proven cirrhosis).
Special Studies: Gastrointestinal: RELAFEN (nabumetone) was compared to aspirin in inducing gastrointestinal blood loss. Food intake was not monitored. Studies utilizing 51Cr-tagged red blood cells in healthy males showed no difference in fecal blood loss after 3 or 4 weeks' administration of 1,000 mg or 2,000 mg of RELAFEN (nabumetone) daily when compared to either placebo-treated or nontreated subjects. In contrast, aspirin 3,600 mg daily produced an increase in fecal blood loss when compared to subjects who received RELAFEN (nabumetone) , placebo, or no treatment. The clinical relevance of the data is unknown.
The following endoscopy trials entered patients who had been previously treated with NSAIDs. These patients had varying baseline scores and different courses of treatment. The trials were not designed to correlate symptoms and endoscopy scores. The clinical relevance of these endoscopy trials, i.e., either G.I. symptoms or serious G.I. events, is not known.
Ten endoscopy studies were conducted in 488 patients who had baseline and post-treatment endoscopy. In 5 clinical trials that compared a total of 194 patients on 1,000 mg of RELAFEN (nabumetone) daily or naproxen 250 mg or 500 mg twice daily for 3 to 12 weeks, treatment with RELAFEN (nabumetone) resulted in fewer patients with endoscopically detected lesions (>3 mm). In 2 trials a total of 101 patients administered 1,000 mg or 2,000 mg of RELAFEN (nabumetone) daily or piroxicam 10 mg to 20 mg for 7 to 10 days, there were fewer patients treated with RELAFEN (nabumetone) with endoscopically detected lesions. In 3 trials of a total of 47 patients on 1,000 mg of RELAFEN (nabumetone) daily or indomethacin 100 mg to 150 mg daily for 3 to 4 weeks, the endoscopy scores were higher with indomethacin. Another 12-week trial in a total of 171 patients compared the results of treatment with 1,000 mg of RELAFEN (nabumetone) daily to ibuprofen 2,400 mg/day and ibuprofen 2,400 mg/day plus misoprostol 800 mcg/day. The results showed that patients treated with RELAFEN (nabumetone) had a lower number of endoscopically detected lesions (>5 mm) than patients treated with ibuprofen alone but comparable to the combination of ibuprofen plus misoprostol. The results did not correlate with abdominal pain.
Other: In 1-week, repeat-dose studies in healthy volunteers, 1,000 mg of RELAFEN (nabumetone) daily had little effect on collagen-induced platelet aggregation and no effect on bleeding time. In comparison, naproxen 500 mg daily suppressed collagen-induced platelet aggregation and significantly increased bleeding time.
Clinical Trials
Osteoarthritis: The use of RELAFEN (nabumetone) in relieving the signs and symptoms of osteoarthritis (OA) was assessed in double-blind, controlled trials in which 1,047 patients were treated for 6 weeks to 6 months. In these trials, RELAFEN (nabumetone) in a dose of 1,000 mg/day administered at night was comparable to naproxen 500 mg/day and to aspirin 3,600 mg/day.
Rheumatoid Arthritis: The use of RELAFEN (nabumetone) in relieving the signs and symptoms of rheumatoid arthritis (RA) was assessed in double-blind, randomized, controlled trials in which 770 patients were treated for 3 weeks to 6 months. RELAFEN (nabumetone) , in a dose of 1,000 mg/day administered at night, was comparable to naproxen 500 mg/day and to aspirin 3,600 mg/day.
In controlled clinical trials of rheumatoid arthritis patients, RELAFEN (nabumetone) has been used in combination with gold, d-penicillamine, and corticosteroids.
Patient Exposure in Clinical Trials of Osteoarthritis and Rheumatoid Arthritis:
In clinical trials with osteoarthritis and rheumatoid arthritis patients, most patients responded to RELAFEN (nabumetone) in doses of 1,000 mg/day administered nightly; total daily dosages up to 2,000 mg were used. In open-labelled studies, 1,490 patients were permitted dosage increases and were followed for approximately 1 year (mode). Twenty percent of patients (n = 294) were withdrawn for lack of effectiveness during the first year of these open-labelled studies. The following table provides patient-exposure to doses used in the US clinical trials:
Table 2. Clinical Double-Blinded and Open-Labelled Trials of RELAFEN (nabumetone) in Osteoarthritis and Rheumatoid Arthritis
|Dose of RELAFEN
|Number of Patients
|Mean/Mode Duration of Treatment (yr)
|500 mg
|1,000 mg
|1,500 mg
|2,000 mg
As with other NSAIDs, the lowest dose should be sought for each patient. Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients' requirements.
Medication Guide for
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
(See the end of this Medication Guide for a list of prescription NSAID medicines.)
What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines may increase the chance of a heart attack or stroke that can lead to death. This chance increases:
- with longer use of NSAID medicines
- in people who have heart disease
NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)".
NSAID medicines can cause ulcers and bleeding in the stomach and intestines at any time during treatment.
Ulcers and bleeding:
- can happen without warning symptoms
- may cause death
The chance of a person getting an ulcer or bleeding increases with:
- taking medicines called "corticosteroids" and "anticoagulants"
- longer use
- smoking
- drinking alcohol
- older age
- having poor health
NSAID medicines should only be used:
- exactly as prescribed
- at the lowest dose possible for your treatment
- for the shortest time needed
What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as:
- different types of arthritis
- menstrual cramps and other types of short-term pain
Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
- if you had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine
- for pain right before or after heart bypass surgery
Tell your healthcare provider:
- about all of your medical conditions
- about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. Keep a list of your medicines to show to your healthcare provider and pharmacist.
- if you are pregnant. NSAID medicines should not be used by pregnant women late in their pregnancy.
- if you are breastfeeding. Talk to your doctor.
What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
|Serious side effects include:
|Other side effects include:
Get emergency help right away if you have any of the following symptoms:
Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:
These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.
Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Aspirin is an NSAID medicine but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.
- Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.
NSAID medicines that need a prescription
|Generic Name
|Cataflam, Voltaren, Arthrotec (combined with misoprostol)
|Lodine, Lodine XL
|Nalfon, Nalfon 200
|Motrin, Tab-Profen, Vicoprofen (combined with hydrocodone), Combunox (combined with oxycodone)
|Indocin, Indocin SR, Indo-Lemmon, Indomethagan
|Mefenamic Acid
|Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac (copackaged with lansoprazole)
|Tolectin, Tolectin DS, Tolectin 600
This Medication Guide has been approved by the U.S. Food and Drug Administration.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
COMMON BRAND NAME(S): Relafen
WARNING: Nonsteroidal anti-inflammatory drugs (including nabumetone) may rarely increase the risk for a heart attack or stroke. The risk may be greater if you have heart disease or increased risk for heart disease (for example, due to smoking, family history of heart disease, or conditions such as high blood pressure or diabetes), or with longer use. This drug should not be taken right before or after heart bypass surgery (CABG).
Also, this drug may infrequently cause serious (rarely fatal) bleeding from the stomach or intestines. This effect can occur without warning symptoms at any time while taking this drug. Older adults may be at higher risk for this effect. (See also Precautions and Drug Interactions sections.)
Stop taking nabumetone and get medical help right away if you notice any of the following rare but serious side effects: bloody or black/tarry stools, persistent stomach/abdominal pain, vomit that looks like coffee grounds, chest/jaw/left arm pain, shortness of breath, unusual sweating, weakness on one side of the body, sudden vision changes, slurred speech.
Talk with your doctor or pharmacist about the risks and benefits of treatment with this medication.
USES: Nabumetone is used to reduce pain, swelling, and joint stiffness from arthritis. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).
If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to treat gout attacks.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using nabumetone and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor, usually once or twice daily with a full glass of water (8 ounces or 240 milliliters). Do not lie down for at least 10 minutes after taking this drug. To prevent stomach upset, take it with food, milk, or an antacid.
Dosage is based on your medical condition and response to treatment. To minimize side effect risks (such as stomach bleeding), use this medication at the lowest effective dose for the shortest possible length of time. Do not increase your dose or take it more often than prescribed. For chronic conditions such as arthritis, continue taking it as directed by your doctor. Discuss the risks and benefits with your doctor or pharmacist.
In certain conditions (such as arthritis), it may take up to 2 weeks when this drug is taken regularly before you notice the full benefits.
If you are taking this drug on an "as needed" basis (not on a regular schedule), remember that pain medications work best if they are used as the first signs of pain occur. If you wait until the pain has worsened, the medication may not work as well.
Tell your doctor if your condition worsens.
SIDE EFFECTS: See also Warning section.
Upset stomach, nausea, vomiting, constipation, diarrhea, gas, dizziness, drowsiness, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if any of these unlikely but serious side effects occur: swelling of the hands or feet (edema), sudden or unexplained weight gain, hearing changes (such as ringing in the ears), mental/mood changes, difficult/painful swallowing, unusual tiredness.
Get medical help right away if any of these rare but very serious side effects occur: change in the amount of urine, unexplained stiff neck.
This drug may rarely cause serious (possibly fatal) liver disease. If you notice any of the following highly unlikely but very serious side effects, stop taking nabumetone and consult your doctor or pharmacist immediately: dark urine, persistent nausea/vomiting, severe stomach/abdominal pain, yellowing eyes or skin.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the Relafen (nabumetone) Side Effects Center for a complete guide to possible side effects
PRECAUTIONS: See also Warning section.
Before taking nabumetone, tell your doctor or pharmacist if you are allergic to it; or to aspirin or other NSAIDs (such as ibuprofen, naproxen, celecoxib); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: asthma (including a history of worsening breathing after taking aspirin or other NSAIDs), bleeding or clotting problems, growths in the nose (nasal polyps), heart disease (such as previous heart attack), high blood pressure, liver disease, stroke, stomach/intestinal/esophagus problems (such as bleeding, ulcers, recurring heartburn).
Kidney problems can sometimes occur with the use of NSAID medications, including nabumetone. Problems are more likely to occur if you are dehydrated, have heart failure or kidney disease, are an older adult, or if you take certain medications (see also Drug Interactions section). Drink plenty of fluids as directed by your doctor to prevent dehydration and tell your doctor right away if you have any unusual change in the amount of urine.
Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).
This drug may make you dizzy or drowsy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely.
This medicine may cause stomach bleeding. Daily use of alcohol and tobacco, especially when combined with this medicine, may increase your risk for stomach bleeding. Limit alcohol and stop smoking. Consult your doctor or pharmacist for more information.
This medication may make you more sensitive to the sun. Avoid prolonged sun exposure, tanning booths or sunlamps. Use a sunscreen and wear protective clothing when outdoors.
Caution is advised when using this drug in the elderly because they may be more sensitive to its side effects, especially stomach bleeding and kidney problems.
Before using this medication, women of childbearing age should talk with their doctor(s) about the benefits and risks (such as miscarriage). Tell your doctor if you are pregnant or if you plan to become pregnant. During pregnancy, this medication should be used only when clearly needed. It is not recommended for use during the first and last trimesters of pregnancy due to possible harm to the unborn baby and interference with normal labor/delivery.
It is unknown if this drug passes into breast milk. Breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Some products that may interact with this drug include: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as losartan, valsartan), cidofovir, corticosteroids (such as prednisone), cyclosporine, lithium, methotrexate, pemetrexed, "water pills" (diuretics such as furosemide, hydrochlorothiazide, triamterene).
This medication may increase the risk of bleeding when taken with other drugs that also may cause bleeding. Examples include anti-platelet drugs such as clopidogrel, "blood thinners" such as dabigatran/enoxaparin/warfarin, among others.
Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (aspirin, NSAIDs such as celecoxib, ibuprofen, or ketorolac). These drugs are similar to nabumetone and may increase your risk of side effects if taken together. However, if your doctor has directed you to take low-dose aspirin to prevent heart attack or stroke (usually at dosages of 81-325 milligrams a day), you should continue taking the aspirin unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.
OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe stomach pain, vomit that looks like coffee grounds, extreme drowsiness, loss of consciousness, slowed or shallow breathing.
NOTES: Do not share this medication with others.
Laboratory and/or medical tests (such as complete blood count, liver and kidney function tests) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.
Non-drug treatment for arthritis that is approved by your doctor (such as weight loss if needed, strengthening and conditioning exercises) may help improve your flexibility, range of motion, and joint function. Consult your doctor for specific instructions.
MISSED DOSE: If you are prescribed this drug on a regular schedule (not just "as needed") and you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details.
Information last revised August 2013. Copyright(c) 2013 First Databank, Inc.
Brand Names: Relafen
Generic Name: nabumetone (Pronunciation: na BUE me tone)
- What is nabumetone (Relafen)?
- What are the possible side effects of nabumetone (Relafen)?
- What is the most important information I should know about nabumetone (Relafen)?
- What should I discuss with my healthcare provider before taking nabumetone (Relafen)?
- How should I take nabumetone (Relafen)?
- What happens if I miss a dose (Relafen)?
- What happens if I overdose (Relafen)?
- What should I avoid while taking nabumetone (Relafen)?
- What other drugs will affect nabumetone (Relafen)?
- Where can I get more information?
What is nabumetone (Relafen)?
Nabumetone is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Nabumetone works by reducing hormones that cause inflammation and pain in the body.
Nabumetone is used to treat pain or inflammation caused by arthritis.
Nabumetone may also be used for other purposes not listed in this medication guide.
Nabumetone 500 mg-EON
oval, white, imprinted with E 145
What are the possible side effects of nabumetone (Relafen)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking nabumetone and seek medical attention or call your doctor at once if you have any of these serious side effects:
- chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance;
- black, bloody, or tarry stools;
- coughing up blood or vomit that looks like coffee grounds;
- swelling or rapid weight gain;
- urinating less than usual or not at all;
- nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
- fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; or
- bruising, severe tingling, numbness, pain, muscle weakness.
Less serious side effects may include:
- upset stomach, mild heartburn or stomach pain, diarrhea, constipation;
- bloating, gas;
- dizziness, headache, nervousness;
- skin itching or rash;
- blurred vision; or
- ringing in your ears.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may report side effects to FDA at 1-800-FDA-1088.
Read the Relafen (nabumetone) Side Effects Center for a complete guide to possible side effects
What is the most important information I should know about nabumetone (Relafen)?
This medicine can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use nabumetone. Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).
Seek emergency medical help if you have symptoms of heart or circulation problems, such as chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
This medicine can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking nabumetone. Older adults may have an even greater risk of these serious gastrointestinal side effects.
Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to nabumetone (such as ibuprofen, ketoprofen, or naproxen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, ketoprofen, or naproxen.
Do not drink alcohol while taking nabumetone. Alcohol can increase the risk of stomach bleeding caused by nabumetone.
Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Nabumetone can make your skin more sensitive to sunlight and sunburn may result.
- Relafen
What should I discuss with my healthcare provider before taking nabumetone (Relafen)?
Taking an NSAID can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use an NSAID. Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).
NSAIDs can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking an NSAID. Older adults may have an even greater risk of these serious gastrointestinal side effects.
Do not use this medication if you are allergic to nabumetone, or if you have a history of allergic reaction to aspirin or other NSAIDs.
Before taking nabumetone, tell your doctor if you are allergic to any drugs, or if you have:
- a history of heart attack, stroke, or blood clot;
- heart disease, congestive heart failure, high blood pressure;
- a history of stomach ulcers or bleeding;
- liver or kidney disease,
- asthma;
- polyps in your nose;
- a bleeding or blood clotting disorder; or
- if you smoke.
If you have any of these conditions, you may need a dose adjustment or special tests to safely take nabumetone.
FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Taking nabumetone during the last 3 months of pregnancy may harm the unborn baby. Do not take nabumetone during pregnancy unless your doctor has told you to.
It is not known whether nabumetone passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Do not give this medicine to a child without the advice of a doctor.
How should I take nabumetone (Relafen)?
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.
If you take nabumetone for a long period of time, your doctor may want to check you on a regular basis to make sure this medication is not causing harmful effects. Do not miss any scheduled visits to your doctor.
Store nabumetone at room temperature away from moisture and heat.
- Relafen
What happens if I miss a dose (Relafen)?
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.
What happens if I overdose (Relafen)?
Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include nausea, vomiting, stomach pain, drowsiness, black or bloody stools, coughing up blood, shallow breathing, fainting, or coma.
What should I avoid while taking nabumetone (Relafen)?
Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to nabumetone (such as ibuprofen, ketoprofen, or naproxen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, ketoprofen, or naproxen.
Do not drink alcohol while taking nabumetone. Alcohol can increase the risk of stomach bleeding caused by nabumetone.
Avoid prolonged exposure to sunlight. Nabumetone may increase the sensitivity of the skin to sunlight. Use a sunscreen and wear protective clothing when exposure to the sun is unavoidable.
What other drugs will affect nabumetone (Relafen)?
Tell your doctor if you are taking an antidepressant such as citalopram (Celexa), duloxetine (Cymbalta), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), or venlafaxine (Effexor). Taking any of these drugs with nabumetone may cause you to bruise or bleed easily.
Before taking nabumetone, tell your doctor if you are taking any of the following drugs:
- a blood thinner such as warfarin (Coumadin);
- lithium (Eskalith, Lithobid);
- methotrexate (Rheumatrex, Trexall);
- diuretics (water pills) such as furosemide (Lasix);
- steroids (prednisone and others);
- aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as etodolac (Lodine), flurbiprofen (Ansaid), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), mefenamic acid (Ponstel), meloxicam (Mobic), nabumetone (Relafen), naproxen (Aleve, Naprosyn), piroxicam (Feldene), and others; or
- an ACE inhibitor such as benazepril (Lotensin), captopril (Capoten), fosinopril (Monopril), enalapril (Vasotec), lisinopril (Prinivil, Zestril), ramipril (Altace), and others.
This list is not complete and there may be other drugs that can interact with nabumetone. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
Where can I get more information?
Your pharmacist can provide more information about nabumetone.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2013 Cerner Multum, Inc. Version: 10.05. Revision date: 12/15/2010.
Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.
- Relafen


text:
Service Alternatives
17 reviews
Kent, WA
Service Alternatives is looking for a Direct Support Professional for a full-time position, during in Kent, WA working at one of our supported living homes for Children with Developmental Disabilities.
What You'll Be Doing:
What You Need to Bring to the Table:
Bonus Points! Otherwise Known As Preferred Qualifications:
What's In It For You?
If This Sounds Like You, Apply Now!
Starting wage for this position is based on applicant's education level.
Job Type: Full-time
Salary: $14.25 to $15.00 /hour
Required education:
Required experience:
Thousands of employers search for candidates on Indeed


text:
Family Law
Family Law Questions? Ask a Family Lawyer Online.
Good Afternoon:
I am going to try to best answer your question. I believe your strongest argument would be that he abandoned the property as he has not retrieved it since 1994. You are would be even stronger if you had reminded him that he needed to remove his items that he requested in the past and he failed to do so. I generally put in a timeframe for removal of items in my agreements in order to avoid this exact problem.
I hope this is helpful and I wish you the best of luck.


text:
Dirty Dining: Life after XO Asian Cuisine
XO Asian Cuisine no longer exists. It's Soho Sushi, and you could almost eat off the basement floor. But Soho still lives in XO's shadow.
Sponsored by:
XO Asian Cuisine no longer exists. It's Soho Sushi, and you could almost eat off the basement floor. But Soho still lives in XO's shadow.
At Elizabeth's Kitchen on 28th Street near US-131 in Wyoming, cockroaches were winning the pest control war.
It started with a quick visit by young cousins to a Grand Rapids restaurant and ended with a rat tail curled up in a crab rangoon.
Nearly three months after the IRS issued Marquinetta Stevenson's tax return, she still hadn't received a check and grew concerned.
Under Oriental Asian Buffet is a history of critical violations, but a history that ends in 2012. There is nothing for the last five years.
The buffet at Oriental Asian Buffet is a big draw, with steam tables offering up everything from frog legs to salmon to crab rangoons.
Target 8 spent months examining more than 10,000 violation reports, along with complaints, enforcement records and reports of illnesses.
Roaches, dangerously cold food, bandages, fingernail clippings, a rat tail. Nothing you'll find on the menu at your favorite restaurant.
After Nestle applied to pump more water in Osceola County, Target 8 investigated how the company has made billions off Michigan water.
"If the jury would have actually heard what was said, I would have never lost my children," a Mecosta County father told lawmakers.
A doctor who already has a suspended medical license was again penalized by the state after new allegations were filed against him.
A woman from Lakeview who was declared dead by the Social Security Administration is very much alive.
After a car dealer kept the only money Summer Lodewyk had for a down payment, a different metro Grand Rapids dealer stepped up to help her.
The Michigan Innocence Clinic, which believes Titus was wrongfully convicted, vowed on Friday to take the case to the state Supreme Court.
A month after Target 8 exposed a builder accused of taking advantage of an Ionia couple, several companies have stepped in to help.


text:
- Home
- Craft & Hobby
- Craft Paint & Stencils
- Finishes and Stains
- EnviroTex® Clear Spray Sealer: 12.5 ounces
EnviroTex® Clear Spray Sealer: 12.5 ounces
Product ID: EN04013
Add stiffness and support to bouquets of artificial flowers with this EnviroTex® clear spray sealer. It seals porous surfaces such as paper or wood with ease and contains 12.5 ounces of clear high-gloss sealant. This EnviroTex® clear spray sealer is also an effective bonding agent for materials that are typically difficult to fuse together, such as metal, glass, and plastics.
Cannot be shipped by airplane.
Color: Clear
Material: Other
Product Type: Varnishes, Glazes & Finishes
Shape: Other
Our Price for 6: $47.82
Unit Price: $7.97
1 clear spray sealer can per package.


text:
The Motorcoach Council submitted an application for a Pepsi Refresh Project Grant and was accepted for the voting cycle that begins on Oct. 1. Each grant asks applicants to fill in the blank after the words "I want to_______." The Motorcoach Council completed the sentence: "I want to Get Motorcoachified and promote Green Travel," supporting the mission of the Council to drive public awareness of the benefits of motorcoach travel through the Get Motorcoachified campaign.
Each month Pepsi is giving away $1.3 million in grants to people, non-profits and businesses that have ideas that will have a positive impact on their communities. The Pepsi Refresh Everything Project is a groundbreaking initiative designed to fund good ideas — big and small — that help refresh the world. Each month 1,000 "good ideas" are presented to the public for voting. Pepsi funds the ideas that receive the most votes.
Starting October 1st, the Motorcoach Council will be calling on all members of the industry, as well as their employees, family members and friends to help secure the votes needed to be awarded a $250,000 grant. This grant will be used to create a compelling nationwide campaign that draws media attention from all across the U.S., coverage that highlights the fact that motorcoach travel is the greenest method of transportation available to consumers today.
The campaign will demonstrate in a unique and tangible way how traveling by coach reduces green house gas emissions and congestion on our nation's roadways, reducing the risks associated with climate change.
The Motorcoach Council is encouraging members of the motorcoach industry to go to www.RefreshEverything.com/GetMotorcoachified each day starting October 1st and vote throughout the month, and to forward the links that are provided on the site to encourage everyone in their network to vote for the Council's grant application.
The ABA Driver Training program was developed by safety experts from industry-leading motorcoach companies and manufacturers.
The dates of the 2020 Marketplace will be Jan. 10 to 14, 2020. This is the first time ABA has come to Omaha for its annual event.
The decline in sales for the second quarter were offset by the continued strength of sales of the new 45-foot motorcoaches, which saw a 2% increase over the same period in 2016.
The 2018 J4500 has been making news for a landmark interior design that's added more comfort, space, and a significant number of aesthetic improvements, all features Coach Atlantic wanted to be first to offer its customers.
The 2018 J4500 features new airline-inspired ceiling lights and aisle puck lights that illuminate the roomier cabin which also features new parcel racks that blend with the front cap of the vehicle.
Receive latest news and stories
The Car and truck fleet and leasing management magazine
managing 10-50 company vehicles
Executive vehicle management
managing public sector vehicles & equipment
The number 1 resource for vocational truck fleets
Serving school transportation professionals in the U.S. and Canada
Global Resource For Limousine and Bus Transportation


text:
Now selling through eBay
Cocktail glassware, shakers, gifts and more!
$ 7.95
Stainless steel wine glass. Perfect for enjoying a glass of wine away from home.
Buy on ebay
Another Martiniware exclusive.
Our Signature series double olive centerpieces make a wonderful addition to any table. This 10 inch martini glass is beautifully detailed with glass olives and red textured pimentos.
** As Featured in Rachel Ray Magazine **
Sexy, stylish and stainless steel. This Martiniware glass is great for serving drinks and Martini themed deserts.
A Martiniware exclusive.
Our Signature series double olive martini glasses make a great gift or a wonderful addition to your own bar. These beautiful 8oz martini glasses are adorned with glass olives and red textured pimentos.
This two-piece glass martini carafe is a great way to enjoy martinis. Mix up a little extra the next time you have guests over, and pour the overflow into these great little 4oz decanters. Keeps an ice cold martini at hand, and allows you to spend more time with friends, less time mixing. Includes (1) bowl and (1) 4oz carafe


text:
SCG America and Kuafu Properties' Manhattan View dishes out only sky-high condos with world-class perks.
With Hudson Yards continuing on course, prospective buyers who are interested in the soon-to-launch master project can already benefit from Manhattan View, the existing rental property on 42nd Street with a newly converted condo cherry on top. As part of what might turn out to be the biggest development project in the history of New York, Manhattan View will offer, unsurprisingly, stunning views from the 51st floor up as the building's top 13 floors encompass the property's condo segment, while the lower floors comprise luxury rental units. The tower already includes an enviable array of amenities and interior designs by three of the best names in the business.
To figure out what was going on at 460 West 42nd Street, we set aside some time to talk with Jeffrey Dvorett, Head of Development at Kuafu Properties. "From Mandarin to English, Kuafu roughly translates to 'bridge,'" explained Dvorett. "The concept behind Kuafu was to create a platform that could bridge Chinese capital and the demands that Chinese investors have with New York investment and development opportunities." One glimpse at Manhattan View and you'll see how the firm has impressively blended New York City taste and style with East Asian scale. "Because our units start on floor 51, our blend is all the way in the sky, which means that we offer studio apartments that are on the fifty-first floor. That never happens. For people who want to have a smaller residence, whether they are empty nesters, pied-à-terre buyers, or those who simply don't have a lot of people living with them, they can buy one of these smaller units at just over $1 million and still enjoy wonderful views and access to amenities without having to buy a four-bedroom apartment."
Speaking of the amenities and perks, Manhattan View includes a smorgasbord. With more than an acre of amenity space, a Yotel, high-end retail names on the ground floor, a dry bar, two different coffee shops, and a signature Frank Gehry public theater featuring fantastic programming, Manhattan View has it all. For the residents alone, the amenities also include a 24-hour concierge by Luxury Attaché, a Dog City playroom, basketball court, Equinox gym, pool, and rooftop lounge. If this seems like you'll only be living in some strange celestial paradise far removed from the outside, then the anticipated development of the surrounding area should have enough to get your head out of the clouds. "We are only at the beginning of the build-up of the Hudson Yards district and the great thing about this property is that residents will have access to the great new buildings that are coming up in the area without being directly on top of them," said Dvorett. "Related Group is planning to build a Neiman Marcus, 100 restaurants, and to install a beautiful sculpture that is being donated to the city. Furthermore, Manhattan View is right next to Hudson Boulevard Park, which ties right into the High Line and allows you to have a green space all the way down to the Whitney."
If you're more of a home body and like to have everything just the way you want it, then don't worry: the Kuafu team have given you the option of choosing between three different interior design styles. Jamie Drake has covered all the base building finishes, i.e. kitchens bathrooms, wood floors, molding, the elevator and lobby, but you can further engage him to outfit your specific unit as well.
Whether you're a fan of the exuberance of Jamie Drake, Michael Gabellini's purity of style, or the multifaceted bespoke designs of the world-renowned Alexandra Champalimaud, Manhattan View sets you up to choose from one of these top-notch interior designers to give your home that little touch that makes it distinctly yours. "Everyone will want different features, so we set up the infrastructure for that. That is the basic package. Because we have a number of different unit sizes, we do not necessarily have a catalogue that shows you what you get when you go with a specific designer's package for an apartment of specific size. Rather, we team up with, say, Michael Gabellini, who will work with the package and develop a custom design for your residence with your input."
So, if the views, the value proposition, and the copious amounts of amenities didn't already sway you, we think the fresh interiors by one of three outstanding design teams just might.
Particulars Manhattan View
Place: Midtown, New York
Property: 147 Residences
Plans: 566 – 2,138 square feet
Price: $1.37 million – $7.25 million
Period: Complete
Amenities: Luxury Attaché 24-hour concierge, grill area, Dog City playroom, basketball court, Equinox gym, pool, office space, rooftop lounge, theater


text:
Lace V-Neck Bodysuit
Standard Price $16.99 Sales Price $11.99
Select Color
Select size
Details content below
- Snap-button crotch
- Partially lined
Product Model Size:Model is 5'11" tall
Online only! Sheer floral lace in a racerback silhouette, makes a stunning one-piece for your outfit! The V-neckline is sweetly scalloped to add a fun touch, with bikini-cut bottoms that provide the perfect tucked-in look below.
Returns content below
Return or exchange in any Charlotte Russe store within 30 days of your ship date, or use the mailing label included in your package to send it back right away.
We do not accept returns on jewelry, swim, intimates, nail polish, fragrance, gift cards, opened beauty products or anything marked as final sale.
You Might Like These Too
Style: 302417563


text:
In each issue, you'll see:
A dozen or more short documentaries on fascinating locals, from a scuba diver in Iceland to a political guide in Palestine.
More than two-dozen photo essays on some of the most breathtaking locations on the planet, each accompanied by local narration and natural soundscapes.
Multiple travel experience videos that showcase some of the most beautiful, awesome, and epic things to do in each country, from snowmobiling on a glacier to discovering Jerusalem's ancient streets.
Humanity is an iPad app for explorers, travelers, and adventurers. It's a travel app that puts storytelling and cultural immersion above all else. Each Humanity issue is created through more than two months of production with the aim of telling unique stories and highlighting fascinating individuals from countries around the world. This isn't a where-to-eat app. We won't show you hotel reviews from your mom. Everything you see on Humanity is original content, created with an immersive iPad experience in mind. We hope to inspire authentic travel and cultural immersion, all while showcasing the people that make a country unique.
As a self-taught photographer moving towards filmmaking, Kerrin's plan of shooting short documentaries on fascinating locals around the world began with a short film of a hostel owner in Iceland's most magnificent region: The Westfjords. A year later, when it came time to create Humanity's first iPad issue, Iceland was at the top of his list. Drawn to countries with magnificent landscapes that mold and shape the people who inhabit them, Kerrin is in constant search for new mountains and terrain to explore. Along with being the cofounder of Xeno Productions, Kerrin's work has been featured on The New York Times, Hollow, Huffington Post, and Fast Company. He lives in various places around the USA with his filmmaking wife, Elaine.
Gaston is an Argentine millennial naturalized as a U.S. citizen. Born to diplomats in Buenos Aires, Gaston inherited an attraction to linguistics and an unquenchable wanderlust that's lured him to more than 60 countries around the world. Proven unfit for corporate life, Gaston became a self-taught filmmaker and subsequent cofounder of Humanity and XENO Productions, through which he channels his fascination for anthropology and moving pictures. In Iceland, you'll likely find Gaston warming up with the locals in one of the many geothermal lagoons.


text:
data load ...
**** in Ploemeur max. 8 Persons
|Short description
In the City; Among nature; Near water
In the small seaside resort of Lomener in southern Brittany, facing the Isle of Groix, on the Morbihan/Finistère border, 10 km west of the bustling city of Lorient. Lorient is a busy town with wide boulevards and a vast array of stylish shops. The excellent zoo at Pont Scorff is just 17 km away.
Environment : Sea setting, overlooking the beach.
Lorient. 10 km. Bustling city with wide boulevards and a vast array of stylish shops, lying on an immense natural harbour protected from the ocean by the isle of Groix. Famous for its fantastic Celtic festival held every August when all Celtic nations meet for a week of music and celebrations. Not to be missed.
Isle of Groix. 10 km. Beautiful 8 km-long steep-sided island with gorgeous beaches. Ideal for a day trip and best visited by bike. Boat crossings from Lorient.
Pont Aven. 40 km. Artists' haunt situated inland from the tip of the Aven estuary. It is a small port popular with tourists and boasting many art galleries. Made famous by Gauguin when he came to paint in the 1880's before leaving for Tahiti and inspired the Pont Aven school.
Auray. 50 km. Charming little town with beautiful old quarter with delightful 15th and 16th century houses. Nearby Ste Anne d'Auray is Brittany's most important place of pilgrimage drawing thousands of pilgrims and tourists from all over the world all year round but especially on July 26th for its "Pardon de Ste Anne" which was attended by Pope John Paul II in 1996.
Golf de Ploemeur Océan, Ploemeur. 6 km. Golf course. 18 holes Par 72 - 5900m. With stunning views over the sea and Groix islands, the vast American style greens with water hazards will delight nature lovers and keen golfers alike. Challenging but fantastic.
Le Poisson Volant, Ploemeur. 6 km. Tree top adventure park. 3 km from the sea, 2 km from Ploemeur, 4 trails with a very nautical theme. Thrills guaranteed!
Golf du Val Quéven, Quéven. 14 km. Golf course. 18 holes Par 72 - 6107m. Superb parkland course with a number of challenges. A firm favourite, it consistently delights the visiting player.
Pont Scorff Zoo, Pont Scorff. 17 km. Fantastic zoo with plenty to occupy and interest the whole family. Allow the whole day to see the whole park and shows. Not to be missed.
Carnac. 60 km. Sought-after and lively seaside resort with excellent sandy beaches. Also renowned for its impressive prehistoric standing stones. A wide range of watersport activities are available as well as a good selection of restaurants and bars.
Pontivy. 70 km. Quaint market town with both a Napoleonic and medieval quarter overlooked by its fabulous 15th century moated castle. Situated on the banks of the Nantes to Brest Canal, it has a lovely atmosphere and boasts a large variety of restaurants and bars. Don't miss the market every Monday morning!
Vannes. 70 km. Delightful and lively city with narrow cobbled streets and medieval buildings crammed around its cathedral. Outside the old walled town, the large colourful port shelters many yachts and is the point of departure for scenic boat trips to the Gulf of Morbihan islands.
Quimper. 70 km. Beautiful riverside city with narrow cobbled streets, a Gothic cathedral and a host of lively bars and restaurants. Famous for its Breton faience pottery and Armor Lux clothes factory which collections are inspired by the colours of the sea and Breton values.
Low cost flights from UK to Brest (1 hr 45 mn), Rennes (2 hrs).
Ferries to Roscoff (2.5 hrs), St Malo (3 hrs).
Sea, Beach: seafront location
Supermarket: 500m
Local shops: 500m
Doctor: 3 km
Town centre: 3 km
Hospital: 15 km (Lorient)
Golf: 6 km
Night club: 10 km
Restaurants/bars: good choice in Lomener and Ploemeur
International airport: Lorient 6 km.


text:
Northcentral Technical College nutrition major
Think about what career is best suited for you, and where you want to study. Request more information now.
Think about what career is best suited for you, and where you want to study. Request more information now.
Think about what career is best suited for you, and where you want to study. Request more information now.
Learn about Northcentral Technical College nutrition major, and registering for elective lectures. Which college degrees give you the best chances of finding employment after graduation? Qualifications for nursing programs vary widely. Learn about the various medical specializations available within technical training programs. Concentrating on Northcentral Technical College nutrition major, for example, you may gain an advantage in job recruiting on-campus. Check with the nutrition department for course registration deadlines, and dieting program requirements. Please use the form above to request admissions info for Northcentral Technical College.
The science of nutrition extends beyond a biochemical analysis of food, assimilation, and digestion within the body. Whole foods provide the energy and nutrients you need to maintain health. Required nutrients include proteins, carbohydrates, fats, vitamins, minerals, and water in abundance. Healthy eating isn't hard in fact, but it's a skill that must be learned. The key to nutritional science is to eat a variety of foods, including vegetables, fruits, and whole-grain products. Further, rehydrate with lots of alkaline, ionized mineral water, and limit your intake of salt, sugar, alcohol, saturated fat, and trans fat in your diet. The high water and fiber content in most fruits and vegetables makes them hard to overeat.
Start your morning by skipping high-sugar, processed cereals, and replace the eggs and some of the cheese in your omelet with vegetables. Swap out some of the meat and cheese in your sandwich with healthier veggie choices such as lettuce, tomatoes, sprouts, cucumbers, and avocado. Instead of a high-calorie snack, such as chips and dip, try baby carrots with hummus, or crunching on a fresh apple. Soft drinks including soda and energy drinks are a huge source of calories in many poor diets. One can of soda contains between 10-12 teaspoons of sugar and 150 calories, so a few soft drinks can quickly bloat your daily calorie intake. Switching to diet soda isn't the answer either. Instead, try switching to water with lemon, unsweetened iced tea, or carbonated water with a splash of juice. Beyond major requirements within the nutrition department, you may consider Bloomsburg University CPR classes as a complementary elective to your primary course of study.
RN - Pediatric ICU (12HR)
John Muir Health
Graduate of an approved nursing program. Current license to practice nursing in the state of California. RN - Pediatric ICU (12HR)..
1 hour ago Nurse RN - Oncology Infusion North
Shands Healthcare
Oncology Nursing Society/Oncology Nursing Certification Corporation Chemotherapy Biotherapy certification within one (1) year of hire or transfer into the..
1 hour ago RN Staff Nurse - IMCU - Good Samaritan Medical Center
Legacy Health System
One year registered nursing experience or completion of either the Legacy Health RN Residency program or a nursing program that is equivalent in content..
5 hours ago RN
University of Colorado Health
A minimum of 6 months relevant nursing experience. Licensed to practice nursing in the State of Colorado. Graduate of an accredited Registered/Professional..
10 hours ago PSYCHIATRIC NURSING ASST I
The University of Iowa
Clean equipment, patient bedside area and nursing unit. Stock and supply patient rooms and Nursing unit..
1 hour ago Manager Oncology - Oncology Unit
Clear Lake Regional Medical Center- Webster
And implementing educational needs for Cardiac Telemetry Care Nursing staff. Geriatric patients and provides fro the development and evaluation of nursing..
4 hours ago


text:
Words that end in hamcs
Found 1 words that end in hamcs. Browse our Scrabble Word Finder, Words With Friends cheat dictionary, and WordHub word solver to find words that end with hamcs. Or use our Unscramble word solver to find your best possible play! Related: Words containing hamcs
- Scrabble
- Words With Friends
- WordHub
- Crossword


text:
Class A Truck Drivers - Owner Operators Great Miles! | Now Hiring in Mesquite!
Parkway TransportMesquite, Texas 75181
Save time and take some hassle out of your job hunt.
Use filters and keywords to sort and save your popular/favorite searches.
Express interest by telling us where you want to work.


text:
Aquarium Cleaning Supplies
Aquarium Decor
Aquarium Filters
When your dog undergoes a surgery and any other eye problems , so we have to take proper care that it does not lick the wound, stiches and so this collar will give support to not disturb the pet while walking or sitting or eating. supremely soft and super comfy experiences in addition to possessing a variety of sizes for greater convenience of pet owners. There are top quality plasticprotective e-collar variants that you can also take a look at. Help your little one recuperate safely with the help of these innovative collars.hemmed edges make it comfortable to wear and protect furniture and walls from being damaged ,Buy Trixie Protective Dog Collar XS online at best and low price in India . Witnessing slowly healing injuries or stitches on your four legged companion can be a difficult experience. It is also problematic to keep your pet from licking or scratching these wounds or even minor rashes that you want him/her to completely refrain from touching . Free Shipping, Cash on Delivery Available .
-Keep your pet from scratching or licking wounds
-Bite and scratch resistant
-Available in different sizes
Good sturdy collar, finishing looks smooth, strong nylon material Exactly what I needed.By Nerella on 21 June 2017